CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity
Anja Sofie Petersen, Inger Marie Sørensen, Harald Schiønning, Tobias Fjeld, Sara Marie Ulv Larsen, Tobias Mathiesen, M. Madsen, Dea Siggaard Stenbæk, Charlotte H. Nykjær, Maria Zofia Grzywacz, Ida L. Klausen, Oliver Overgaard-Hansen, Kristoffer Brendstrup‐brix, Kristían Línnet, Sys Stybe Johansen, Patrick M. Fisher, Rigmor Jensen, Gitte M. Knudsen
Headache: The Journal of Head and Face Pain 2024 DOI: 10.1111/head.14656 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label clinical trial Peer reviewed |
|---|---|
| Sample size | 10 |
| Population | Patients with chronic cluster headache |
| Intervention | Psilocybin |
| Dose | 0.14 mg/kg |
| Duration | 10 weeks (4-week baseline, 3 weekly doses in weeks 5-7, 4-week follow-up) |
| Topics | Psilocybin |
| Keywords | Functional connectivity Reduction mathematics Hallucinogen Communication |
| Citations | 29 |
| Key findings | Psilocybin reduced attack frequency by 31% in patients with chronic cluster headache, and changes in hypothalamic–diencephalic functional connectivity correlated with the reduction. |
Abstract
Abstract Objective To evaluate the feasibility and prophylactic effect of psilocybin as well as its effects on hypothalamic functional connectivity (FC) in patients with chronic cluster headache (CCH).
Background: CCH is an excruciating and difficult‐to‐treat disorder with incompletely understood pathophysiology, although hypothalamic dysfunction has been implicated. Psilocybin may have beneficial prophylactic effects, but clinical evidence is limited.
Methods: In this small open‐label clinical trial, 10 patients with CCH were included and maintained headache diaries for 10 weeks. Patients received three doses of peroral psilocybin (0.14 mg/kg) on the first day of weeks five, six, and seven. The first 4 weeks served as baseline and the last 4 weeks as follow‐up. Hypothalamic FC was determined using functional magnetic resonance imaging the day before the first psilocybin dose and 1 week after the last dose.
Results: The treatment was well tolerated. Attack frequency was reduced by mean (standard deviation) 31% (31) from baseline to follow‐up ( p FWER = 0.008). One patient experienced 21 weeks of complete remission. Changes in hypothalamic–diencephalic FC correlated negatively with a percent change in attack frequency ( p FWER = 0.03, R = −0.81), implicating this neural pathway in treatment response.
Conclusion: Our results indicate that psilocybin may have prophylactic potential and implicates the hypothalamus in possible treatment response. Further clinical studies are warranted.
Comparable studies
Other non-randomized and open-label trials on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression | 2016 | Open-label feasibility trial | n = 12 |
| Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression | 2017 | Open-label trial | n = 20 |
| Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers | 2014 | Open-label pilot study | n = 15 |
| Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression | 2018 | Clinical trial | n = 20 |
| Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) | 2006 | Controlled clinical trial |
Citations in the library
Cited by 26
- Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal of the Neurological Sciences May 15, 2024
- Psilocybin for the treatment of Alzheimer’s disease Frontiers in Neuroscience July 10, 2024
- Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial Frontiers in Pain Research March 18, 2025
- Psilocybin as a novel treatment for chronic pain British Journal of Pharmacology November 29, 2024
- Low‐dose psilocybin in short‐lasting unilateral neuralgiform headache attacks: results from an open‐label phase Ib ascending dose study Headache: The Journal of Head and Face Pain September 20, 2024
and 21 more in the library
Cites 16
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV) PLoS One August 31, 2010
- Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Neuropsychopharmacology January 26, 2019
- Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors Science February 16, 2023
- Psychedelics as Medicines: An Emerging New Paradigm Clinical Pharmacology & Therapeutics November 4, 2016
and 11 more in the library